Xianjun Fang

Prof. Dr. Xianjun Fang

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Cancer Letters
Verified
Journal Article
Closed access
YMYibao Ma
Yibao Ma
STSarah M. Temkin
Sarah M. Temkin
AHAdam M. Hawkridge
Adam M. Hawkridge
CGChunqing Guo
Chunqing Guo
WWWei Wang
Wei Wang
Xianjun FangXianjun Fang
Xianjun Fang

31 December 2018 in Cancers
Verified
Journal Article
Open access
PDF file
YMYibao Ma
Yibao Ma
WWWei Wang
Wei Wang
MIMichael O. Idowu
Michael O. Idowu
UOUnsong Oh
Unsong Oh
XWXiang-Yang Wang
Xiang-Yang Wang
Xianjun FangXianjun Fang
Xianjun Fang
The recent progresses in understanding of cancer glycolytic phenotype have offered new strategies to manage ovarian cancer and other malignancies. However, therapeutic targeting of glycolysis to treat cancer remains unsuccessful due to complex mechanisms of tumor glycolysis and the lack of selective, potent and safe glycolytic inhibitors. Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer. Notably, BAY-876 has not been evaluated in any cell or preclinical animal models since its discovery. We herein took advantage of BAY-876 and molecular approaches to study GLUT1 regulation, targetability, and functional relevance to cancer glycolysis. The anti-tumor activity of BAY-876 was evaluated with ovarian cancer cell line- and patient-derived xenograft (PDX) models. Our results show that inhibition of GLUT1 is sufficient to block basal and stress-regulated glycolysis, and anchorage-dependent and independent growth of ovarian cancer cells. BAY-876 dramatically inhibits tumorigenicity of both cell line-derived xenografts and PDXs. These studies provide direct evidence that GLUT1 is causally linked to the glycolytic phenotype in ovarian cancer. BAY-876 is a potent blocker of GLUT1 activity, glycolytic metabolism and ovarian cancer growth, holding promise as a novel glycolysis-targeted anti-cancer agent.

29 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YMYibao Ma
Yibao Ma
WWWei Wang
Wei Wang
TDTeja Devarakonda
Teja Devarakonda
HZHuiping Zhou
Huiping Zhou
XWXiang-Yang Wang
Xiang-Yang Wang
Xianjun FangXianjun Fang
Xianjun Fang
Fatty acid oxidation (FAO) is a key bioenergetic pathway often dysregulated in diseases. The current knowledge on FAO regulators in mammalian cells is limited and sometimes controversial. Previous FAO analyses involve nonphysiological culture conditions or lack adequate quantification. We herein described a convenient and quantitative assay to monitor dynamic FAO activities of mammalian cells in physiologically relevant settings. The method enabled us to assess various molecular and pharmacological modulators of the FAO pathway in established cell lines, primary cells and mice. Surprisingly, many previously proposed FAO inhibitors such as ranolazine and trimetazidine lacked FAO-interfering activity. In comparison, etomoxir at low micromolar concentrations was sufficient to saturate its target proteins and to block cellular FAO function. Oxfenicine, on the other hand, acted as a partial inhibitor of FAO. As another class of FAO inhibitors that transcriptionally repress FAO genes, antagonists of peroxisome proliferator-activated receptors (PPARs), particularly that of PPARα, significantly decreased cellular FAO activity. Our assay also had sufficient sensitivity to monitor upregulation of FAO in response to environmental glucose depletion and other energy-demanding cues. Altogether this study provided a reliable FAO assay and a clear picture of biological properties of potential FAO modulators in the mammalian system.

29 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MCMartial CAILLAUD
Martial CAILLAUD
NPNipa H. Patel
Nipa H. Patel
WTWisam Toma
Wisam Toma
AWAlyssa White
Alyssa White
DTDanielle Thompson
Danielle Thompson
MDM.Imad Damaj
M.Imad Damaj
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a major adverse effect of this chemotherapeutic agent that is used in the treatment of a number of solid malignancies. PIPN leads notably to burning pain, cold and mechanical allodynia. PIPN is thought to be a consequence of alterations of mitochondrial function, hyperexcitability of neurons, nerve fiber loss, oxidative stress and neuroinflammation in dorsal root ganglia (DRG) and spinal cord (SC). Therefore, reducing neuroinflammation could potentially attenuate neuropathy symptoms. Peroxisome proliferator-activated receptor-α (PPAR-α) nuclear receptors that modulate inflammatory responses can be targeted by non-selective agonists, such as fenofibrate, which is used in the treatment of dyslipidemia. Methods: Our studies tested the efficacy of a fenofibrate diet (0.2% and 0.4%) in preventing the development of PIPN. Paclitaxel (8 mg/kg) was administered via 4 intraperitoneal (i.p.) injections in C57BL/6J mice (both male and female). Mechanical and cold hypersensitivity, wheel running activity, sensory nerve action potential (SNAP), sciatic nerve histology, intra-epidermal fibers, as well as the expression of PPAR-α and neuroinflammation were evaluated in DRG and SC. Results: Fenofibrate in the diet partially prevented the development of mechanical hypersensitivity but completely prevented cold hypersensitivity and the decrease in wheel running activity induced by paclitaxel. The reduction in SNAP amplitude induced by paclitaxel was also prevented by fenofibrate. Our results indicate that suppression of paclitaxel-induced pain by fenofibrate involves the regulation of PPAR-α expression through reduction in neuroinflammation. Finally, co-administration of paclitaxel and the active metabolite of fenofibrate (fenofibric acid) did not interfere with the suppression of tumor cell growth or clonogenicity by paclitaxel in ovarian and breast cancer cell lines. Conclusions: Taken together, our results show the therapeutic potential of fenofibrate in the prevention of PIPN development.

Verified
Journal Article
Open access
PDF file
SSSumit Saha
Sumit Saha
Xianjun FangXianjun Fang
Xianjun Fang
CGChris Green
Chris Green
ANINDITA DASANINDITA DAS
ANINDITA DAS
Diabetic cardiomyopathy is a critical diabetes-mediated co-morbidity characterized by cardiac dysfunction and heart failure, without predisposing hypertensive or atherosclerotic conditions. Metabolic insulin resistance, promoting hyperglycemia and hyperlipidemia, is the primary cause of diabetes-related disorders, but ambiguous tissue-specific insulin sensitivity has shed light on the importance of identifying a unified target paradigm for both the glycemic and non-glycemic context of type 2 diabetes (T2D). Several studies have indicated hyperactivation of the mammalian target of rapamycin (mTOR), specifically complex 1 (mTORC1), as a critical mediator of T2D pathophysiology by promoting insulin resistance, hyperlipidemia, inflammation, vasoconstriction, and stress. Moreover, mTORC1 inhibitors like rapamycin and their analogs have shown significant benefits in diabetes and related cardiac dysfunction. Recently, FDA-approved anti-hyperglycemic sodium–glucose co-transporter 2 inhibitors (SGLT2is) have gained therapeutic popularity for T2D and diabetic cardiomyopathy, even acknowledging the absence of SGLT2 channels in the heart. Recent studies have proposed SGLT2-independent drug mechanisms to ascertain their cardioprotective benefits by regulating sodium homeostasis and mimicking energy deprivation. In this review, we systematically discuss the role of mTORC1 as a unified, eminent target to treat T2D-mediated cardiac dysfunction and scrutinize whether SGLT2is can target mTORC1 signaling to benefit patients with diabetic cardiomyopathy. Further studies are warranted to establish the underlying cardioprotective mechanisms of SGLT2is under diabetic conditions, with selective inhibition of cardiac mTORC1 but the concomitant activation of mTORC2 (mTOR complex 2) signaling.

26 August 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
WWWei Wang
Wei Wang
JWJinhua Wu
Jinhua Wu
AMAbir Mukherjee
Abir Mukherjee
THTianhai He
Tianhai He
XWXiang‐Yang Wang
Xiang‐Yang Wang
Xianjun FangXianjun Fang
Xianjun Fang
Epithelial ovarian carcinoma tissues express high levels of tumor necrosis factor‐alpha (TNF‐α) and other inflammatory cytokines. The underlying mechanism leading to the abnormal TNF‐α expression in ovarian cancer remains poorly understood. In the current study, we demonstrated that lysophosphatidic acid (LPA), a lipid mediator present in ascites of ovarian cancer patients, induced expression of TNF‐α mRNA and release of TNF‐α protein in ovarian cancer cells. LPA also induced expression of interleukin‐1β (IL‐1β) mRNA but no significant increase in IL‐1β protein was detected. LPA enhanced TNF‐α mRNA through NF‐κB‐mediated transcriptional activation. Inactivation of ADAM17, a disintegrin and metalloproteinase, with a specific inhibitor TMI‐1 or by shRNA knockdown prevented ovarian cancer cells from releasing TNF‐α protein in response to LPA, indicating that LPA‐mediated TNF‐α production relies on both transcriptional upregulations of the TNF‐α gene and the activity of ADAM17, the membrane‐associated TNF‐α‐converting enzyme. Like many other biological responses to LPA, induction of TNF‐α by LPA also depended on the transactivation of the epidermal growth factor receptor (EGFR). Interestingly, our results revealed that ADAM17 was also the shedding protease responsible for the transactivation of EGFR by LPA in ovarian cancer cells. To explore the biological outcomes of LPA‐induced TNF‐α, we examined the effects of a TNF‐α neutralizing antibody and recombinant TNF‐α soluble receptor on LPA‐stimulated expression of pro‐tumorigenic cytokines and chemokines overexpressed in ovarian cancer. Blockade of TNF‐α signaling significantly reduced the production of IL‐8, IL‐6, and CXCL1, suggesting a hierarchy of mechanisms contributing to the robust expression of the inflammatory mediators in response to LPA in ovarian cancer cells. In contrast, TNF‐α inhibition did not affect LPA‐dependent cell proliferation. Taken together, our results establish that the bioactive lipid LPA drives the expression of TNF‐α to regulate an inflammatory network in ovarian cancer.